New Huntington's drug enters human testing
NCT ID NCT07339514
Summary
This early-stage study is testing a new injection called ER2001 in people with early Huntington's disease. The main goals are to check if the treatment is safe, how the body processes it, and to look for early signs it might help. Participants receive weekly injections for 6 weeks and are followed for safety for 24 weeks afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510080, China
-
First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.